MONECO Advisors LLC Lowers Stock Holdings in Johnson & Johnson (NYSE:JNJ)

MONECO Advisors LLC decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 1.5% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 61,913 shares of the company’s stock after selling 958 shares during the quarter. Johnson & Johnson makes up approximately 1.8% of MONECO Advisors LLC’s holdings, making the stock its 7th largest holding. MONECO Advisors LLC’s holdings in Johnson & Johnson were worth $9,704,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Sivia Capital Partners LLC acquired a new stake in Johnson & Johnson in the 4th quarter valued at about $592,000. PVG Asset Management Corp increased its holdings in shares of Johnson & Johnson by 28.8% during the fourth quarter. PVG Asset Management Corp now owns 3,899 shares of the company’s stock worth $611,000 after purchasing an additional 872 shares during the period. Cove Private Wealth LLC bought a new position in shares of Johnson & Johnson during the fourth quarter worth approximately $1,390,000. Wahed Invest LLC increased its holdings in shares of Johnson & Johnson by 7.8% during the fourth quarter. Wahed Invest LLC now owns 41,171 shares of the company’s stock worth $6,453,000 after purchasing an additional 2,988 shares during the period. Finally, Red Mountain Financial LLC bought a new position in Johnson & Johnson in the fourth quarter valued at approximately $320,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

JNJ has been the topic of a number of research reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research note on Monday, May 6th. Morgan Stanley cut their price target on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 17th. Bank of America cut their price target on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a report on Wednesday, April 17th. The Goldman Sachs Group initiated coverage on shares of Johnson & Johnson in a report on Thursday, May 30th. They set a “neutral” rating and a $160.00 price target on the stock. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $175.00 target price on shares of Johnson & Johnson in a report on Monday. Eight analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $174.07.

Johnson & Johnson Stock Down 0.0 %

Shares of Johnson & Johnson stock traded down $0.01 during trading on Monday, hitting $145.53. The company’s stock had a trading volume of 2,246,186 shares, compared to its average volume of 7,332,086. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.94 and a current ratio of 1.17. The company has a fifty day simple moving average of $148.38 and a two-hundred day simple moving average of $154.71. The company has a market capitalization of $350.24 billion, a PE ratio of 9.10, a P/E/G ratio of 2.42 and a beta of 0.53. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $175.97.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.64 by $0.07. The company had revenue of $21.38 billion for the quarter, compared to the consensus estimate of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The firm’s revenue was up 2.3% compared to the same quarter last year. During the same quarter last year, the firm posted $2.68 earnings per share. Equities research analysts predict that Johnson & Johnson will post 10.63 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st were given a dividend of $1.24 per share. The ex-dividend date of this dividend was Monday, May 20th. This represents a $4.96 annualized dividend and a dividend yield of 3.41%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s dividend payout ratio (DPR) is presently 30.92%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.